
Hope for People Living with Rare Skin Conditions
Living with a rare skin condition such as Olmsted Syndrome, Pachyonychia Congenita, or Ichthyosis can be painful and challenging, affecting daily activities, and overall well-being and in some cases life threating . Orvida is developing new treatments that target the underlying biological cause of these disorders, offering hope for meaningful and lasting improvement. Clinical studies are currently underway, and eligible patients may have the opportunity to participate.
If you or a loved one would like to learn more...
Contact usIf you or a loved one would like to learn more...

Ongoing and Planned Clinical Trials of Lanavatrep
Orvida is conducting clinical trials of its oral TRPV3 inhibitor, lanavatrep, across multiple sites. Current and planned studies focus on Olmsted Syndrome and pachyonychia congenita, as well as ichthyosis.
Contact usNow Recruiting
Study in Adult Olmsted Syndrome (TRPV3-pEDD) Patients


France
Hôpital Necker
Paris
Prof. Alain Hovnanian
UK
Royal London Hospital
London
Prof. Edel O’Toole
USA
Northwestern University Dept of Dermatology
Chicago, IL
Prof. Amy Paller
Contact us
Orphan designation approved (FDA, EMA) | NCT07090889

Upcoming Clinical Trial
Pachyonychia Congenita
Lanavatrep (pEDD-PC)
Initiate enrolment planned during 2026
.png)
Interested in Learning More?
Contact us by email clinicaltrials@orvidapharma.com or fill in the form below and we’ll get back to you
Thank You
We will contact you as soon as possible
Oops! Something went wrong while submitting the form.
